Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VCN 01

Drug Profile

VCN 01

Alternative Names: VCN-01

Latest Information Update: 06 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VCN Biosciences
  • Class Antineoplastics; Gene therapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Hyaluronidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pancreatic cancer; Retinoblastoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 03 Sep 2019 Efficacy data from the phase I P-VCNA-001 and P-VCNA-002 trials in Pancreatic cancer released by VCN Biosciences
  • 20 Mar 2019 Phase-I clinical trials in Squamous cell cancer (Combination therapy, Second-line therapy or greater, Recurrent, Metastatic disease, Late-stage disease) in Spain (IV) (NCT03799744)
  • 29 Jan 2019 VCN Biosciences received regulatory approval to initiate phase I trial of VCN 01 in combination with durvalumab for recurrent and or metastatic squamous cell carcinoma of the head and neck
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top